American Home Products Corporation had received Final Judicial Approval on January 3, 2002 regarding a settlement related to Fen-Phen, the miracle obesity drug. This settlement has been a result of many reports linking Fen-Phen to serious medical problems.

This judicial approval paved way for patients suffering from severe side effects of Fen-Phen. It allowed anyone suffering from fatal Fen-Phen side effect to collect his or her claim for compensation. The only condition required is that they should be eligible for this claim that is their suffering must be a result of Fen-Phen use.

Fen-Phen is a weight loss pill. It is a combination drug containing fenfluramine and phentermine. Fenfluramine is nearly similar to other anti obesity drug dexfenfluramine, sold with name Redux. Whereas Phentermine was also sold with many brand names including Phentrol for treatment of obesity. The combination was launched in the market as a miracle drug to reduce obesity. It was withdrawn from U.S. market in 1997 due to its alleged link with heart valve diseases.

Phentermine was approved in 1959 by the United States Food & Drug Administration. It was approved to be used as anti obesity drug. Fenfluramine was approved by the FDA to be used as a drug to reduce obesity in 1973.  It was approved to be used as a part of a anti obesity program containing diet and exercise. Both the drugs were approved for short-term use only.

The anti obesity drug Fen-Phen was developed by Dr. Michael Weintraub. He was a researcher at the University of Rochester. He found out that lower doses of Fen-Phen, a combination of Fenfluramine and Phentermine, could lead to suppression of appetite. It could lead to weight loss and lesser side effects in the combination form. Their side effects are higher when these drugs are used alone.

In 1992 a study revealed that this drug increases the rate of weight loss compared to other anti obesity drugs. It was later linked with serious health problems. In 1997 in safety alert regarding use of Fen-Phen was issued by FDA. Later it was withdrawn from the market same year.

The withdrawal of Fen-Phen paved way for numerous lawsuits related to Fen-Phen side effects against manufacturers of Fen-Phen. There were many class action lawsuits filed against Fen-Phen related to Primary Pulmonary Hypertension or PPH. Fen-Phen has been linked to Primary Pulmonary Hypertension. It is a severe diseases, which could lead to fatal results. The symptoms of primary pulmonary hypertension are shortness of breath, angina pectoris, syncope or swelling in the ankle. It is linked with Fenfluramine. Studies reveal that long-term use of this drug could lead to increased risk of developing primary pulmonary hypertension or PPH. It is serious condition, which could lead to fatal results. Patients using Fenfluramine should immediately seek medical help if they develop any exercise intolerance, as it could be a symptom of Primary pulmonary Hypertension.

Though Fen-Phen has been withdrawn from the market patients who have used it before withdrawal are diagnosed with sever side effects such as Primary Pulmonary Hypertension even now. This has lead to several lawsuits. The approval for settlement is going to prove beneficial for them.